The tactical trap in pharma CX – and how to avoid it
Dominic Tyer
JUNE 25, 2024
Customer experience (CX) is not a new discipline for pharma, but it does continue to provide the industry with growing pains
Sat.Jun 22, 2024 - Fri.Jun 28, 2024
130 
Daiichi’s lung cancer ADC rejected by FDA in blow to first project under Merck partnership
Fierce Pharma
JUNE 26, 2024
In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody drug conjugate (ADC) patritumab deruxtecan. | In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody drug conjugate patritumab deruxtecan.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Who Is Responsible for the High Cost of Prescription Drugs? One Advocate Weighs In
MedCity News
JUNE 24, 2024
Multiple stakeholders are to blame for prescription drug costs, including pharmaceutical companies and PBMs, according to Merith Basey, executive director of Patients for Affordable Drugs. The post Who Is Responsible for the High Cost of Prescription Drugs? One Advocate Weighs In appeared first on MedCity News.
How to Increase Sales in a Medical Field
David Bagga
JUNE 25, 2024
Medical Device Sales Academy How to Increase Sales in a Medical Field Here are some of the ways that contribute towards increasing medical sales: 1. Get in-depth Product Knowledge A thorough understanding of your products is crucial in medical deals. This includes the technical specifications, clinical applications, and benefits. Attend training sessions, read product manuals, […] The post How to Increase Sales in a Medical Field appeared first on.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine
Pharmaceutical Technology
JUNE 25, 2024
Novavax has sought EMA approval for its updated JN.1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above.
With FDA nod, Verona’s Ohtuvayre is set to Jack up the COPD market
Fierce Pharma
JUNE 26, 2024
Thirteen years after his passing, Sir David Jack still looms as an innovative force in healthcare. | Verona Pharma has earned an FDA approval for Ohtuvayre, a potential blockbuster with a novel mechanism of action, to treat patients with chronic obstructive pulmonary disorder (COPD). It is the first novel treatment advancement in the indication in more than a decade.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Zealand Pharma rakes in $1bn in funding for obesity drugs
pharmaphorum
JUNE 26, 2024
Fresh from reporting encouraging results with its obesity drug candidate petrelintide, Zealand Pharma has raised an impressive $1 billion from a new share offering.The Danish biotech started the fundraising process earlier this week with an expectation of raising $900 million but easily overshot that target, evidence once again of huge investor interest in companies developing a new generation of obesity drugs.
AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
Pharmaceutical Technology
JUNE 26, 2024
AstraZeneca has received Japanese approval for Tagrisso plus chemotherapy as first-line treatment for non-small cell lung cancer (NSCLC).
Alnylam CEO touts 'big-win scenario' for Amvuttra in closely watched heart disease trial
Fierce Pharma
JUNE 24, 2024
In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events in patient | In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events.
Medicare Telehealth Flexibilities Will Expire In December. Congress Needs To Act Swiftly, Experts Say
MedCity News
JUNE 23, 2024
Telehealth advocates are calling on Congress to act quickly on Medicare telehealth flexibilities, which are set to expire at the end of the year. Doing so would help key healthcare stakeholders prepare. The post Medicare Telehealth Flexibilities Will Expire In December. Congress Needs To Act Swiftly, Experts Say appeared first on MedCity News.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
PharmaVoice
JUNE 27, 2024
Neuroscience pipelines are reawakening as biotechs prove to the pharma giants that the field is still worth the investment.
Amazon bundles its telehealth services under one brand
pharmaphorum
JUNE 28, 2024
Amazon’s strategy in telehealth has coalesced around a pay-per-visit and subscription-based model under a new brand – Amazon One Medical.
Rallying in RSV vaccine race, Pfizer gains contract win over GSK in the UK
Fierce Pharma
JUNE 24, 2024
After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. | After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. And what better way to do it than to win a major contract in your rival’s home country? The U.K. government has selected Pfizer to supply 5 million doses of its RSV shot Abrysvo over the next two years.
AHA Urges Congress to Stop CMS from Enforcing Minimum Staffing Requirements for Nursing Homes
MedCity News
JUNE 26, 2024
The American Hospital Association sent letters to the Senate and House urging them to support legislation that would prevent the CMS from enforcing its final rule on minimum staffing requirements for long-term care facilities. The organization argued that the mandate could lead nursing homes to reduce capacity or close altogether. The post AHA Urges Congress to Stop CMS from Enforcing Minimum Staffing Requirements for Nursing Homes appeared first on MedCity News.
Ahead of its upcoming decision date, a competitor takes aim at KarXT
PharmaVoice
JUNE 25, 2024
The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.
EvolutionaryScale emerges with $142m for AI drug discovery
pharmaphorum
JUNE 26, 2024
AI in drug discovery start-up EvolutionaryScale raises $142m in seed financing for its LLM-powered platform for designing protein structures.
Merck's Capvaxive gears up to challenge Pfizer's dominant Prevnar with CDC panel backing
Fierce Pharma
JUNE 28, 2024
After scoring approval as the world’s first pneumococcal disease vaccine made specifically for adults earlier this month, Merck’s Capvaxive passed the next test in its bid to take on Pfizer an | The recommendation sets up Merck's new pneumococcal disease vaccine to potentially capture some of Pfizer's market share.
Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets
MedCity News
JUNE 25, 2024
Liquid biopsy company Grail is now an independent, publicly traded company. While the separation from Illumina ends a protracted antitrust battle, Grail is still in the early stages of a long-term strategy to win regulatory validation and payor coverage for its multi-cancer early detection test. The post Illumina Spin-Off Now Complete, Grail Sets Out on Its Own on the Public Markets appeared first on MedCity News.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
New multiple sclerosis treatment option granted in EU
European Pharmaceutical Review
JUNE 25, 2024
The European Commission has approved the first twice-yearly injection for relapsing and primary progressive multiple sclerosis (RMS and PPMS). Roche highlighted that as a 10-minute injection, OCREVUS ® (ocrelizumab) subcutaneous has the same twice-yearly schedule as the intravenous (IV) infusion, which was the first therapeutic to be approved for both RMS and PPMS.
Vertex islet cell therapy gets type 1 diabetics off insulin
pharmaphorum
JUNE 23, 2024
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 were able to come off insulin within a year
Novo Nordisk wins approval in China for GLP-1 obesity drug Wegovy
Fierce Pharma
JUNE 25, 2024
On the market for three years in China, Novo Nordisk’s diabetes drug Ozempic (semaglutide) is racing toward blockbuster sales in the world’s second most populous country. | China’s National Medical Products Administration (NMPA) has blessed Novo Nordisk's Wegovy with marketing approval to treat people with a body mass index (BMI) of at least 30 or between 27 and 30 for those with one weight-related risk factor.
How AI Can Help Solve Healthcare’s Data Problem
MedCity News
JUNE 28, 2024
By prioritizing data accuracy and interoperability, stakeholders can begin to unlock the potential of AI in healthcare. The post How AI Can Help Solve Healthcare’s Data Problem appeared first on MedCity News.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Can Moderna’s COVID-flu combo shot improve flagging vaccination rates?
PharmaVoice
JUNE 25, 2024
A COVID and flu duo could ease manufacturing and administration, potentially driving higher vaccination rates, said Moderna’s VP of North American medical affairs.
FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP
pharmaphorum
JUNE 23, 2024
Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it hopes could find a use in more than a dozen diseases.
Haleon reels in $633M with sale of ex-US nicotine replacement unit to Dr. Reddy's
Fierce Pharma
JUNE 26, 2024
With U.K. consumer health giant Haleon slimming down and India’s Dr. Reddy’s Laboratories beefing up its over-the-counter offerings, the two have arrived at a deal that makes sense for both. | Haleon has continued its push to divest, selling its nicotine replacement therapy (NRT) business outside of the United States to Dr. Reddy’s for 500 million pounds ($633 million).
Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials
MedCity News
JUNE 28, 2024
Alumis’s lead drug candidate blocks TYK2, an inflammation target that’s already addressed by Sotyktu, a Bristol Myers Squibb drug approved for plaque psoriasis. Alumis plans to begin two Phase 3 tests in this indication later this year. The post Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials appeared first on MedCity News.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
After an obesity deal with Novo, Omega’s new business head is on the hunt for more partners
PharmaVoice
JUNE 24, 2024
With a career focused on striking deals, Kaan Cartel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.
Verona’s first-in-class COPD drug ‘could transform market’
pharmaphorum
JUNE 27, 2024
Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years, according to Verona.
Amid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod
Fierce Pharma
JUNE 24, 2024
Following Novo Nordisk’s recent Wegovy approval to cut heart risks in adults with obesity, Eli Lilly appears to be homing in on the next potential label expansion for its rival GIP/GLP-1 weigh | Late last week, Lilly shared detailed results from its phase 3 SURMOUNT-OSA study, which found that Zepbound at the 10 mg and 15 mg doses aced its primary and secondary endpoints in obese patients with obstructive sleep apnea (OSA).
What Do Experts Make of Risant Health’s Newest Acquisition?
MedCity News
JUNE 27, 2024
While it it’s too early to judge the success of Kaiser Permanente’s Risant Health, the company’s first two acquisitions show a commitment to adjoining organizations with a strong focus on population health — as well as a dedication to spreading Kaiser’s value-based care delivery models across the country. The post What Do Experts Make of Risant Health’s Newest Acquisition?
Let's personalize your content